Spyre Therapeutics (FRA:3920) E10: €-33.06 (As of Mar. 2026)


FRA:3920 Spyre Therapeutics Inc FRA:3920
33 GF Score
Price €77.00
! 4 Warning Signs
View Full Analysis

What is Spyre Therapeutics E10?

Spyre Therapeutics FRA:3920 33 E10 is €-33.06 as of Mar. 2026. GuruFocus rates FRA:3920 with a GF Score™ of 33/100. The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Spyre Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was €-0.640. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-33.06 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-06-30), Spyre Therapeutics's current stock price is €77.00. Spyre Therapeutics's E10 for the quarter that ended in Mar. 2026 was €-33.06. Spyre Therapeutics's Shiller PE Ratio of today is .


Spyre Therapeutics  (FRA:3920) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Spyre Therapeutics E10 Related Terms


Spyre Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Spyre Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Spyre Therapeutics E10 Chart

Spyre Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 -44.38 -35.63

Spyre Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -45.36 -38.95 -36.09 -35.63 -33.06

FRA:3920 vs MIRM, RYTM, PTGX: E10 Comparison

For the Biotechnology subindustry, Spyre Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Spyre Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spyre Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Spyre Therapeutics's Shiller PE Ratio falls into.


FRA:3920
33GF Score
Spyre Therapeutics Inc FRA:3920
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Spyre Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Spyre Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.64/330.2130*330.2130
=-0.640

Current CPI (Mar. 2026) = 330.2130.

Spyre Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -10.235 241.018 -14.023
201609 -10.469 241.428 -14.319
201612 -7.821 241.432 -10.697
201703 -10.986 243.801 -14.880
201706 -10.458 244.955 -14.098
201709 -10.068 246.819 -13.470
201712 -8.027 246.524 -10.752
201803 -9.935 249.554 -13.146
201806 -9.844 251.989 -12.900
201809 -11.570 252.439 -15.135
201812 -14.064 251.233 -18.485
201903 -13.054 254.202 -16.957
201906 -12.169 256.143 -15.688
201909 -14.982 256.759 -19.268
201912 -14.625 256.974 -18.793
202003 -12.896 258.115 -16.498
202006 -8.880 257.797 -11.374
202009 -6.155 260.280 -7.809
202012 -6.987 260.474 -8.858
202103 -5.880 264.877 -7.330
202106 -2.075 271.696 -2.522
202109 -6.588 274.310 -7.931
202112 -6.876 278.802 -8.144
202203 -8.399 287.504 -9.647
202206 -6.386 296.311 -7.117
202209 -4.888 296.808 -5.438
202212 -4.427 296.797 -4.925
202303 -4.567 301.836 -4.996
202306 -37.049 305.109 -40.097
202309 -0.806 307.789 -0.865
202312 -1.607 306.746 -1.730
202403 -0.662 312.332 -0.700
202406 -0.787 314.175 -0.827
202409 -1.213 315.301 -1.270
202412 -0.774 315.605 -0.810
202503 -0.555 319.799 -0.573
202506 -0.524 322.561 -0.536
202509 -0.157 324.800 -0.160
202512 -0.598 324.054 -0.609
202603 -0.640 330.213 -0.640

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of €-33.06 mean?
Spyre Therapeutics (FRA:3920) has a E10 of €-33.06 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Spyre Therapeutics and its competitors.
Is Spyre Therapeutics' E10 too high?
Spyre Therapeutics' current E10 is €-33.06. Overall, Spyre Therapeutics has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Spyre Therapeutics' E10 compare to MIRM and RYTM?
Spyre Therapeutics' E10 of €-33.06 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Spyre Therapeutics and its competitors. Spyre Therapeutics's current E10 is €-33.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Spyre Therapeutics stock overvalued right now?
Spyre Therapeutics (FRA:3920) has a current E10 of €-33.06. The current E10 is €-33.06. Spyre Therapeutics' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Spyre Therapeutics (FRA:3920), the current E10 is €-33.06 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Spyre Therapeutics Business Description

Other Exchanges SYRE:USA3920:Germany
Address 221 Crescent Street, Suite 105, Building 23, Waltham, MA, USA, 02453
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting ?4?7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
33GF Score

Get the complete analysis for FRA:3920

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€77.00
Price